Current Edition

20

NBE Therapeutics Closes a CHF 20 Million Financing by Novo Holdings A/S

NBE Therapeutics AG, a biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for improved cancer therapy, today announces a CHF 20 million extension of the Series …

Continue Reading →